Abstracts tagged "treatment"

Abstract Number: 455 • 2013 ACR/ARHP Annual Meeting
Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Peter Dawes¹, Aleksandar Dimic², Mark C. Genovese³, Désiréé van der Heijde⁴, Martin Jenkins⁵, Chris O'Brien⁶, Barry Oemar⁷, Jiri Vencovsky⁸ and Michael Weinblatt⁹, ¹Department of Rheumatology, University of North Staffordshire NHS Trust, Stoke-on-Trent, United Kingdom, ²Rheumatology Institute, Niška Banja, Serbia, ³Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁶AstraZeneca R&D Wilmington, Wilmington, DE, ⁷AstraZeneca R&D Boston, Boston, MA, ⁸Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic, ⁹Division of Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Fostamatinib (Fosta) is a novel spleen tyrosine kinase (SYK) inhibitor. The Phase II TASKi studies showed benefit in patients (pts) with active rheumatoid arthritis…
Abstract Number: 2336 • 2013 ACR/ARHP Annual Meeting
Phase 2 Evaluation Of PF-04171327, a Dissociated Agonist Of The Glucocorticoid Receptor, For The Treatment Of Rheumatoid Arthritis In Patients With An Inadequate Response To Methotrexate
Thomas Stock¹, Dona Fleishaker², Xin Wang², Arnab Mukherjee² and Charles Mebus², ¹Pfizer Inc., Collegeville, PA, ²Pfizer Inc., Groton, CT
Background/Purpose: PF-04171327, a pro drug of PF-00251802, is under investigation as a potential dissociated agonist of the glucocorticoid receptor (DAGR). PF-00251802 is a selective high-affinity…
Abstract Number: 1337 • 2013 ACR/ARHP Annual Meeting
Nearly Pain Free Self-Administration Of Methotrexate Using An Investigational Auto-Injector: Results Of a Phase-2 Clinical Trial In Rheumatoid Arthritis Patients With Mild-To-Severe Functional Limitations
Alan J. Kivitz¹, David McLain², John Hill³, Bruce Freundlich⁴, Jonathan Jaffe⁵ and Kaushik J. Dave⁶, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Rheumatology, McLain Medical Associates, PC, Birmingham, AL, ³Avail Clinical Research, DeLand, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Clinical Development, Antares Pharma Inc, Ewing, NJ, ⁶Product Development, Antares Pharma Inc, Ewing, NJ
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. Limitations of systemic exposure of oral MTX can affect its efficacy. Subcutaneous (SC) MTX…
Abstract Number: 456 • 2013 ACR/ARHP Annual Meeting
Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor -á Antagonist
Mark Genovese¹, Désiréé van der Heijde², Edward Keystone³, Alberto Spindler⁴, Claude-Laurent Benhamou⁵, Arthur Kavanaugh⁶, Edward Fudman⁷, Kathy Lampl⁸, Chris O'Brien⁸, Emma Duffield⁹, Jeffrey Poiley¹⁰ and Michael Weinblatt¹¹, ¹Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, ²Leiden University Medical Center, Leiden, Netherlands, ³University of Toronto, Toronto, ON, Canada, ⁴Centro Medico Privado de Reumatologia, Tucuman, Argentina, ⁵Centre Hospitalier Régional d'Orléans, Orleans, France, ⁶University of California San Diego, San Diego, CA, ⁷Austin Rheumatology Research PA, Austin, TX, ⁸AstraZeneca R&D Wilmington, Wilmington, DE, ⁹AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ¹⁰Arthritis Associates, Orlando, FL, ¹¹Division of Rheumatology, Brigham & Women's Hospital, Boston, MA
Background/Purpose: Fostamatinib (Fosta) is an oral SYK inhibitor. This 24-wk study (NCT01197755) compared Fosta vs placebo (PBO) on methotrexate (MTX) treatment in patients (pts) with…
Abstract Number: 2340 • 2013 ACR/ARHP Annual Meeting
Persistent Use Of Biologic Therapies At Lower Than Recommended Dosing Among Rheumatoid Arthritis Patients Enrolled In The US Medicare Program
Jie Zhang¹, Fenglong Xie², Elizabeth S. Delzell³, Huifeng Yun³, James Lewis⁴, Kevin Haynes⁵, Lang Chen⁶, Kenneth G. Saag⁷ and Jeffrey R. Curtis⁸, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, ⁶Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama at Birmingham, Birmingham, AL
Title: Persistent Use of Biologic Therapies at Lower Than Recommended Dosing among Rheumatoid Arthritis Patients Enrolled in the US Medicare ProgramBackground/Purpose: Biologic therapy is associated…
Abstract Number: 1354 • 2013 ACR/ARHP Annual Meeting
Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen
Jaime Pachon¹, Alan Kivitz², Kay-Uwe Heuer³ and Uwe Pichlmeier³, ¹Arthritis and Rheumatic Care Center, Miami Research Associates, South Miami, FL, ²Altoona Center for Clinical Research, Duncansville, PA, ³medac GmbH, Wedel, Germany
Background/Purpose: Methotrexate (MTX) is the most commonly used and recommended DMARD for the treatment of RA. SC administered MTX is well absorbed and appears to…
Abstract Number: 459 • 2013 ACR/ARHP Annual Meeting
Transaminase Levels and Hepatic Events Observed During Tocilizumab Treatment: Pooled Analysis Of Long-Term Clinical Trial Safety Data In Patients With Rheumatoid Arthritis
MC Genovese¹, Joel M. Kremer², Ronald F. van Vollenhoven³, Rieke Alten⁴, Juan José Scali⁵, Ariella Kelman⁶, Lucy Rowell⁷ and Laura Pitts⁷, ¹Division of Immunology and Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Center for Rheumatology, Albany Medical College, Albany, NY, ³Karolinska Institute, Stockholm, Sweden, ⁴Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁵Durand University Hospital, Buenos Aires, Argentina, ⁶Genentech, South San Francisco, CA, ⁷Roche, Welwyn Garden City, United Kingdom
Background/Purpose: The interleukin-6 receptor inhibitor tocilizumab (TCZ) has demonstrated efficacy in improving signs/symptoms, reducing joint damage, and improving function and is well tolerated in patients…
Abstract Number: 2313 • 2013 ACR/ARHP Annual Meeting
Pain-Related Anxiety As a Barrier To Use Of Methotrexate In Rheumatoid Arthritis: Comparing Conventional Vial, Needles, and Syringe With An Investigational Auto-Injector In Healthy Volunteers
Victoria L. Ruffing¹ and Kaushik J. Dave², ¹Medicine JHAAC, Johns Hopkins University, Baltimore, MD, ²Product Development, Antares Pharma Inc, Ewing, NJ
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. Limitations of systemic exposure of oral MTX can affect its efficacy. Subcutaneous (SC) MTX…
Abstract Number: 1302 • 2013 ACR/ARHP Annual Meeting
Application of Cytostatic Agent Kinesin Eg5 Inhibitor Litronesib (KF89617) On Rat Adjuvant-Induced Arthritis and Mouse Type II Collagen-Induced Arthritis
Ichiro Miki¹ and Masako Uchii², ¹Fuji Research Park, Kyowa Hakko Kirin, Co., Ltd., Shizuoka, Japan, ²Fuji Research Park, Kyowa Hakko Kirin Co., Ltd., Shizuoka, Japan
Background/Purpose: Kinesins are family of motor proteins that are involved in mitosis and intracellular transport of vesicles and organelles. The mitotic kinesin, Eg5, acts…
Abstract Number: 428 • 2013 ACR/ARHP Annual Meeting
Correlation Between Objective and Patient Self-Reported Clinical Improvement After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: Data From Repeat Study
Ioan Ancuta¹, Catalin Codreanu², Ruxandra Ionescu³, Magda Parvu⁴, Dan Nemes⁵, Rodica Chirieac⁶, Paulina Ciurea⁷, Maria Suta⁸, Andra Balanescu⁹, Eugenia Mociran¹⁰ and Elena Rezus¹¹, ¹“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ²Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania, ⁴Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, ⁵Rehabilitation and Rheumatology, ”Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, ⁶C.M.I. Rodica Chirieac, Iasi, Romania, ⁷Emergency County Hospital, Craiova, Romania, ⁸Emergency County Hospital, Constanta, Romania, ⁹Internal Medicine and Rheumatology, University of Medicine and Pharmacy, Bucharest, Romania, ¹⁰Emergency County Hospital Dr Constantin Opis, Maramures, Romania, ¹¹Rheumatology, Recovering Clinical Hospital, Iasi, Romania
Background/Purpose: Rituximab (RTX) has been evaluated in many clinical trials and objective assessment of rheumatoid arthritis (RA) activity must comply with Treat to Target principles.…
Abstract Number: 2324 • 2013 ACR/ARHP Annual Meeting
Persistence On Biologics Is Associated With Concomitant Methotrexate Use Among Rheumatoid Arthritis Patient
Jie Zhang¹, Fenglong Xie², Elizabeth S. Delzell³, Huifeng Yun³, James Lewis⁴, Kevin Haynes⁵, Lang Chen⁶ and Jeffrey R. Curtis⁷, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, ⁶Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL
Persistence on Biologics is Associated with Concomitant Methotrexate Use among Rheumatoid Arthritis Patient Background/Purpose: Concomitant methotrexate (MTX) is associated with improved treatment efficacy in randomized controlled…
Abstract Number: 1307 • 2013 ACR/ARHP Annual Meeting
Synovial Subset–Derived Baseline Serum Biomarkers Segregate Rheumatoid Arthritis Patients Into Subgroups With Distinct Serum Protein and Clinical Characteristics
A. Francesca Setiadi, Nicholas Lewin-Koh, Sarah Kummerfeld, David F. Choy, Cécile T.J. Holweg, Sally Fischer, An Song and Michael J. Townsend, Genentech, South San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a heterogeneous disease. Predictive biomarkers have the potential to enhance treatment effectiveness by enabling identification of likely responders to a…
Abstract Number: 436 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Study Of a Sequential Therapy Of Tocilizumab and, If Initially Inadequately Responded To Tocilizumab, Followed By Rituximab In Patients With Rheumatoid Arthritis and Inadequate Response To Traditional Disease Modifying Anti-Rheumatic Drugs (MIRAI)-Interim Analysis 2
Thomas Doerner¹, Hans Peter Tony², Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kaestner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, S. Wagner⁸, Marvin A. Peters⁹ and Christof Iking-Konert¹⁰, ¹Dept Int Med (Charite), Humdoldt Univ, Berlin, Germany, ²Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ³Division of Rheumatology, University of Munich, Munich, Germany, ⁴Ambulant Centres for Rheumatology, Rheumatologist, Ludwigsfelde, Germany, ⁵Outpatient Department of Rheumatology, Ambulantes Rheumazentrum Erfurt, Germany,, Erfurt, Germany, ⁶Centre for Inflammatory Joint Diseases, Munich, Germany, ⁷Rheumapraxis, Aachen, Germany, ⁸Internistische Schwerpunktpraxis für Rheumatologie, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluates a sequential exposure to two defined biologics under rigorous study conditions within a homogeneous population of patients (pts) who inadequately…
Abstract Number: 2328 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
Jürgen Wollenhaupt¹, Joel Silverfield², Eun Bong Lee³, Susan P. Wood⁴, Ketti K. Terry⁴, Hiroyuki Nakamura⁵, Yukako Ohno⁵, David Gruben⁴, Birgitta Benda⁶, Lisy Wang⁴ and Richard Riese⁴, ¹Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ²Healthpoint Medical Group, Tampa, FL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Japan Inc, Tokyo, Japan, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
Abstract Number: 951 • 2013 ACR/ARHP Annual Meeting
The Anti-IL-17A Monoclonal Antibody Secukinumab (AIN457) Inhibits Pro-Inflammatory Mediator Release From Human Primary Synoviocytes Costimulated With IL-17 and TNF
Christine Huppertz, Marija Curcic Djuric, Robert Hennze and Frank Kolbinger, Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland
Background/Purpose: Fibroblast-like synoviocytes (FLS) are targets of the pro-inflammatory IL-17 cytokines and a major source of inflammatory mediators in the inflamed synovium in rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].